Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in

Rui Gou1, Hui Dong1, Bei Lin1

  • 1Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China; Key Laboratory of Maternal-Fetal Medicine of Liaoning Province, Key Laboratory of Obstetrics and Gynecology of Higher Education of Liaoning Province, Liaoning, China.

Life Sciences
|September 17, 2020
PubMed

Insights

Homologous recombination deficiency (HRD) is crucial for cancer treatment. Genomic scar assays can accurately assess HRD, guiding personalized therapy with platinum salts and PARP inhibitors for better patient outcomes.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Defective DNA repair is a hallmark of cancer, with BRCA1/2 mutations impacting homologous recombination repair (HRR).
  • BRCA1/2 mutations predict sensitivity to platinum salts and PARP inhibitors in various cancers, including breast and ovarian.
  • Homologous recombination deficiency (HRD) can also arise from epigenetic modifications and mutations in other HRR genes, leading to a 'BRCAness' phenotype.

Purpose of the Study:

  • To review the therapeutic effects of platinum salts and PARP inhibitors in breast and ovarian cancers.
  • To clarify the predictive value of genomic scar assays in assessing clinical benefits for different patient groups and treatments.
  • To propose limitations and optimizations for current HRD scoring methods.

Main Methods:

  • Review of therapeutic effects and predictive values of genomic scar assays in clinical trials.
  • Analysis of current HRD scoring methods, their limitations, and potential optimizations.

Main Results:

  • Genomic scar assays are utilized in clinical trials to assess patient benefit.
  • Accurate HRD assessment is essential for personalized treatment strategies.
  • Optimizing genomic scar assays can expand drug applicability and improve clinical decision-making.

Conclusions:

  • Genomic scar assays offer a valuable tool for screening patient populations who will benefit most from platinum salts and PARP inhibitors.
  • Further optimization of HRD scoring methods is needed to refine patient selection and treatment strategies.
  • Personalized treatment decisions based on accurate HRD assessment can enhance therapeutic efficacy and patient outcomes.